MannKind Corporation (NASDAQ: MNKD) stock surged 7.13% in pre-market trading on Thursday, February 27, 2025, following the company's impressive fourth-quarter and full-year 2024 financial results. The biopharmaceutical company reported record revenues and significant debt reduction, fueling investor optimism about its growth prospects.

During the earnings call, MannKind highlighted several key achievements and provided updates on its product pipeline, which are driving the stock's strong performance:

- The company's endocrine business unit, led by its flagship product Afrezza (inhaled insulin), achieved record revenues of $23 million in Q4 2024 and $82 million for the full year. MannKind is preparing for the potential launch of Afrezza in the pediatric market, with approval expected in early 2026.

- MannKind announced a collaboration with Amphastar, enabling the promotion of Afrezza through its U.S. sales force, which is expected to enhance its pediatric footprint. Additionally, the company is seeking a label expansion for Afrezza and plans to launch the product in India in the second half of 2025.

- The company reported positive updates on its pipeline candidates, including clofazimine inhalation suspension and nintedanib DPI, which are progressing through clinical trials and regulatory discussions. These promising treatments could potentially address unmet needs in various therapeutic areas.

- MannKind's partnership with United Therapeutics for Tyvaso DPI, an inhaled treatment for pulmonary arterial hypertension, continues to be a significant revenue driver. The company is well-positioned to benefit from potential label expansions and product line extensions for Tyvaso DPI.